Dermapharm Holding SE (DMP) - Total Liabilities

Latest as of March 2026: €1.54 Billion EUR ≈ $1.80 Billion USD

Based on the latest financial reports, Dermapharm Holding SE (DMP) has total liabilities worth €1.54 Billion EUR (≈ $1.80 Billion USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore DMP long-term investment intensity to see how much of total assets are deployed in long-term investments.

Dermapharm Holding SE - Total Liabilities Trend (2013–2025)

This chart illustrates how Dermapharm Holding SE's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see DMP asset base.

Dermapharm Holding SE Competitors by Total Liabilities

The table below lists competitors of Dermapharm Holding SE ranked by their total liabilities.

Company	Country	Total Liabilities
Jointo Energy Investment Co Ltd Hebei SHE:000600	China	CN¥27.65 Billion
Reysas Gayrimenkul Yatirim Ortakligi AS IS:RYGYO	Turkey	TL10.90 Billion
Guangdong Goworld Co Ltd SHE:000823	China	CN¥2.66 Billion
Jiangsu Leili Motor Corp Ltd SHE:300660	China	CN¥3.09 Billion
IBF Financial Holdings Co Ltd TW:2889	Taiwan	NT$451.77 Billion
Gempharmatech Co. Ltd. A SHG:688046	China	CN¥630.58 Million
Beijing Jetsen Tech Co SHE:300182	China	CN¥2.86 Billion
Neutron Holdings, Inc. Common Stock NASDAQ:LIME	USA	$493.56 Million

Liability Composition Analysis (2013–2025)

This chart breaks down Dermapharm Holding SE's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See how leveraged is Dermapharm Holding SE's balance sheet to measure how much of total assets are equity-financed.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	2.00	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	2.08	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.68	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Dermapharm Holding SE's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Dermapharm Holding SE (2013–2025)

The table below shows the annual total liabilities of Dermapharm Holding SE from 2013 to 2025.

Year	Total Liabilities	Change
2025-12-31	€1.50 Billion ≈ $1.76 Billion	+2.12%
2024-12-31	€1.47 Billion ≈ $1.72 Billion	-8.91%
2023-12-31	€1.62 Billion ≈ $1.89 Billion	+83.52%
2022-12-31	€880.34 Million ≈ $1.03 Billion	-2.95%
2021-12-31	€907.13 Million ≈ $1.06 Billion	+0.81%
2020-12-31	€899.81 Million ≈ $1.05 Billion	+18.34%
2019-12-31	€760.38 Million ≈ $888.97 Million	+69.54%
2018-12-31	€448.50 Million ≈ $524.34 Million	+31.29%
2017-12-31	€341.62 Million ≈ $399.39 Million	+36.16%
2016-12-31	€250.89 Million ≈ $293.32 Million	-0.53%
2015-12-31	€252.22 Million ≈ $294.88 Million	-14.96%
2014-12-31	€296.59 Million ≈ $346.74 Million	-3.90%
2013-12-31	€308.62 Million ≈ $360.80 Million	--

About Dermapharm Holding SE

XETRA:DMP Germany Drug Manufacturers - Specialty & Generic

Market Cap

$2.20 Billion

€1.88 Billion EUR

Market Cap Rank

#6245 Global

#941 in Germany

Share Price

€37.90

Change (1 day)

+1.34%

52-Week Range

€32.05 - €51.80

All Time High

€80.48